Per Pfeiffer

Medicin og biovidenskab

1. Colorectal Neoplasms 100%
2. Oxaliplatin 68%
3. Cetuximab 42%
4. Survival 41%
5. Drug Therapy 38%
6. Irinotecan 36%
7. Pancreatic Neoplasms 35%
8. Fluorouracil 26%
9. Aerosols 26%
10. Neoplasms 24%
11. Therapeutics 23%
12. Capecitabine 21%
13. Adenocarcinoma 18%
14. Bevacizumab 18%
15. Rectal Neoplasms 17%
16. Neoplasm Metastasis 17%
17. Progression-Free Survival 14%
18. trifluridine tipiracil 13%
19. Mutation 13%
20. Leucovorin 12%
21. Biomarkers 10%
22. Gastrointestinal Neoplasms 10%
23. Population 10%
24. Combination Drug Therapy 10%
25. Radiotherapy 9%
26. Stomach Neoplasms 9%
27. Denmark 9%
28. XELOX 9%
29. gemcitabine 8%
30. pembrolizumab 8%
31. Epirubicin 8%
32. Cell-Free Nucleic Acids 7%
33. Safety 7%
34. Adjuvant Chemotherapy 7%
35. Quality of Life 7%
36. Esophageal Neoplasms 6%
37. Elderly 6%
38. Confidence Intervals 6%
39. Geriatric Assessment 6%
40. MicroRNAs 6%
41. Cisplatin 6%
42. ErbB Receptors 6%
43. S 1 (combination) 5%
44. Carcinoembryonic Antigen 5%
45. encorafenib 5%
46. C-Reactive Protein 5%
47. Colonic Neoplasms 5%
48. Randomized Controlled Trials 5%
49. Interleukin-6 5%
50. N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid 5%